{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:04:41Z","timestamp":1793253881588,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adoptive T cell therapy (ACT) is effective against hematologic cancers, but the mechanisms underlying durable responses in solid tumors remain unclear. We show that adoptively transferred CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells that eradicate established murine tumors promote expansion of host CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells exhibiting tumor-reactive and tissue-resident phenotypes that contribute to tumor elimination. Mechanistically, tumor necrosis factor (TNF) from transferred cells induces dendritic cell (DC)-dependent expansion of host CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, conferring protection against ACT-resistant tumor cells lacking the targeted antigen. Lymphodepleting preconditioning promotes expansion of transferred cells and primary tumor eradication but impairs host antitumor immunity and abrogates protection against ACT-resistant tumors. In human tumors, increased TNF\/DC\/CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell profiles correlate with favorable ACT responses and improved survival. These findings reveal a TNF-dependent interplay between transferred and host CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells underlying durable antitumor immunity that is impaired by lymphodepleting preconditioning in mouse models, suggesting an underappreciated mechanism of ACT resistance.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-71082-y","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T01:38:12Z","timestamp":1774921092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T\u00a0cell therapy in mouse models"],"prefix":"10.1038","volume":"17","author":[{"given":"Diego","family":"Figueroa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1480-9783","authenticated-orcid":false,"given":"Juan Pablo","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Hern\u00e1ndez-Oliveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Ardiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6516-0957","authenticated-orcid":false,"given":"Sof\u00eda","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Bustamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Malav\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6916-3962","authenticated-orcid":false,"given":"Felipe","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8417-1891","authenticated-orcid":false,"given":"Felipe","family":"G\u00e1lvez-Cancino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5857-4793","authenticated-orcid":false,"given":"Manuel","family":"Varas-Godoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9318-343X","authenticated-orcid":false,"given":"Maria Rosa","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Borgna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5576-1478","authenticated-orcid":false,"given":"Alvaro","family":"Lladser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"71082_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier, B. et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580, 257\u2013262 (2020).","journal-title":"Nature"},{"key":"71082_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","volume":"37","author":"MK Ruhland","year":"2020","unstructured":"Ruhland, M. K. et al. Visualizing synaptic transfer of tumor antigens among dendritic cells. Cancer Cell 37, 786\u2013799.e5 (2020).","journal-title":"Cancer Cell"},{"key":"71082_CR3","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638\u2013652 (2014).","journal-title":"Cancer Cell"},{"key":"71082_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.immunol.20.100201.131730","volume":"20","author":"JH Russell","year":"2002","unstructured":"Russell, J. H. & Ley, T. J. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20, 323\u2013370 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"71082_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1126\/science.1254803","volume":"346","author":"S Ariotti","year":"2014","unstructured":"Ariotti, S. et al. Skin-resident memory CD8+ T cells trigger a state of tissue-wide pathogen alert. Science 346, 101\u2013105 (2014).","journal-title":"Science"},{"key":"71082_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.1254536","volume":"346","author":"JM Schenkel","year":"2014","unstructured":"Schenkel, J. M. et al. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346, 98\u2013101 (2014).","journal-title":"Science"},{"key":"71082_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"71082_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba7918","volume":"5","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8+ T cells. Sci. Immunol. 5, eaba7918 (2020).","journal-title":"Sci. Immunol."},{"key":"71082_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","volume":"45","author":"DT Utzschneider","year":"2016","unstructured":"Utzschneider, D. T. et al. T cell factor 1-expressing memory-like CD8+ T cells sustain the immune response to chronic viral infections. Immunity 45, 415\u2013427 (2016).","journal-title":"Immunity"},{"key":"71082_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"J-C Beltra","year":"2020","unstructured":"Beltra, J.-C. et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity 52, 825\u2013841.e8 (2020).","journal-title":"Immunity"},{"key":"71082_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies, A., Zehn, D. & Utzschneider, D. T. Precursor exhausted T cells: key to successful immunotherapy? Nat. Rev. Immunol. 20, 128\u2013136 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"71082_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1+ PD-1+ CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211.e10 (2019).","journal-title":"Immunity"},{"key":"71082_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"71082_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"71082_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62\u201368 (2015).","journal-title":"Science"},{"key":"71082_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1158\/2326-6066.CIR-15-0215","volume":"4","author":"TD Prickett","year":"2016","unstructured":"Prickett, T. D. et al. Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol. Res. 4, 669\u2013678 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"71082_CR17","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","volume":"25","author":"S Stevanovic","year":"2019","unstructured":"Stevanovic, S. et al. A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus\u2013associated epithelial cancers. Clin. Cancer Res. 25, 1486\u20131493 (2019).","journal-title":"Clin. Cancer Res."},{"key":"71082_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","volume":"25","author":"W Scheper","year":"2019","unstructured":"Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89\u201394 (2019).","journal-title":"Nat. Med."},{"key":"71082_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Liu, Z., Wei, W. & Li, Y. TCR engineered T cells for solid tumor immunotherapy. Exp. Hematol. Oncol. 11, 38 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"71082_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jha2.356","volume":"3","author":"U Patel","year":"2022","unstructured":"Patel, U. et al. CAR T cell therapy in solid tumors: a review of current clinical trials. EJHaem 3, 24\u201331 (2022).","journal-title":"EJHaem"},{"key":"71082_CR21","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer, J. N. et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol. Ther. 25, 2245\u20132253 (2017).","journal-title":"Mol. Ther."},{"key":"71082_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"71082_CR23","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Zhu, L., Zhang, H., Chen, S. & Xiao, Y. C. A. R.-T. Cell therapy in hematological malignancies: current opportunities and challenges. Front. Immunol. 13, 927153 (2022).","journal-title":"Front. Immunol."},{"key":"71082_CR24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).","journal-title":"Science"},{"key":"71082_CR25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","volume":"21","author":"JD Chan","year":"2021","unstructured":"Chan, J. D. et al. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat. Rev. Immunol. 21, 769\u2013784 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"71082_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/14712598.2021.1857361","volume":"21","author":"N Bechman","year":"2021","unstructured":"Bechman, N. & Maher, J. Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy\u2013what are we doing; where are we going?. Expert Opin. Biol. Ther. 21, 627\u2013637 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"71082_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1609874","volume":"8","author":"B Wylie","year":"2019","unstructured":"Wylie, B. et al. Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens. Oncoimmunology 8, 1609874 (2019).","journal-title":"Oncoimmunology"},{"key":"71082_CR28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","volume":"3","author":"HT Khong","year":"2002","unstructured":"Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation of \u2018tumor escape\u2019 phenotypes. Nat. Immunol. 3, 999\u20131005 (2002).","journal-title":"Nat. Immunol."},{"key":"71082_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151\u2013167 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"71082_CR30","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"71082_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"F Braig","year":"2017","unstructured":"Braig, F. et al. Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129, 100\u2013104 (2017).","journal-title":"Blood"},{"key":"71082_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"71082_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1182\/blood.2023021672","volume":"143","author":"J Duell","year":"2024","unstructured":"Duell, J. et al. Sequential antigen-loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell redirecting therapy. Blood 143, 685\u2013696 (2024).","journal-title":"Blood"},{"key":"71082_CR34","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","volume":"5","author":"HJ Jackson","year":"2015","unstructured":"Jackson, H. J. & Brentjens, R. J. Overcoming antigen escape with CAR T-cell therapy. Cancer Discov. 5, 1238\u20131240 (2015).","journal-title":"Cancer Discov."},{"key":"71082_CR35","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai, J. et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat. Immunol. 21, 914\u2013926 (2020).","journal-title":"Nat. Immunol."},{"key":"71082_CR36","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1172\/JCI126199","volume":"129","author":"SR Walsh","year":"2019","unstructured":"Walsh, S. R. et al. Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. J. Clin. Invest. 129, 5400\u20135410 (2019).","journal-title":"J. Clin. Invest."},{"key":"71082_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.abd4344","volume":"6","author":"M Boulch","year":"2021","unstructured":"Boulch, M. et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci. Immunol. 6, 1\u20136 (2021).","journal-title":"Sci. Immunol."},{"key":"71082_CR38","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","volume":"11","author":"D Alizadeh","year":"2021","unstructured":"Alizadeh, D. et al. IFN\u03b3 is critical for CAR T cell\u2013mediated myeloid activation and induction of endogenous immunity. Cancer Discov. 11, 2248\u20132265 (2021).","journal-title":"Cancer Discov."},{"key":"71082_CR39","doi-asserted-by":"publisher","first-page":"e1442163","DOI":"10.1080\/2162402X.2018.1442163","volume":"7","author":"F G\u00e1lvez-Cancino","year":"2018","unstructured":"G\u00e1lvez-Cancino, F. et al. Vaccination-induced skin-resident memory CD8+ T cells mediate strong protection against cutaneous melanoma. Oncoimmunology 7, e1442163 (2018).","journal-title":"Oncoimmunology"},{"key":"71082_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.4049\/jimmunol.2400151","volume":"213","author":"JF Isaacs","year":"2024","unstructured":"Isaacs, J. F. et al. CD39 is expressed on functional effector and tissue-resident memory CD8+ T cells. J. Immunol. 213, 588\u2013599 (2024).","journal-title":"J. Immunol."},{"key":"71082_CR41","first-page":"11","volume":"3","author":"K Chiba","year":"2006","unstructured":"Chiba, K., Matsuyuki, H., Maeda, Y. & Sugahara, K. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell. Mol. Immunol. 3, 11\u201319 (2006).","journal-title":"Cell. Mol. Immunol."},{"key":"71082_CR42","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.4049\/jimmunol.165.11.6278","volume":"165","author":"C Brunner","year":"2000","unstructured":"Brunner, C. et al. Enhanced dendritic cell maturation by TNF-\u03b1 or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J. Immunol. 165, 6278\u20136286 (2000).","journal-title":"J. Immunol."},{"key":"71082_CR43","doi-asserted-by":"publisher","first-page":"15137","DOI":"10.1073\/pnas.261570598","volume":"98","author":"AA Lighvani","year":"2001","unstructured":"Lighvani, A. A. et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc. Natl. Acad. Sci. USA 98, 15137\u201315142 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71082_CR44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.4049\/jimmunol.1102727","volume":"189","author":"JM Curtsinger","year":"2012","unstructured":"Curtsinger, J. M., Agarwal, P., Lins, D. C. & Mescher, M. F. Autocrine IFN-\u03b3 promotes naive CD8 T cell differentiation and synergizes with IFN-\u03b1 to stimulate strong function. J. Immunol. 189, 659\u2013668 (2012).","journal-title":"J. Immunol."},{"key":"71082_CR45","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.immuni.2005.04.004","volume":"22","author":"A Kissenpfennig","year":"2005","unstructured":"Kissenpfennig, A. et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22, 643\u2013654 (2005).","journal-title":"Immunity"},{"key":"71082_CR46","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723.e4 (2017).","journal-title":"Cancer Cell"},{"key":"71082_CR47","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"71082_CR48","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst, J., Ahrends, T., B\u0105ba\u0142a, N., Melief, C. J. M. & Kastenm\u00fcller, W. CD4+ T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635\u2013647 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"71082_CR49","doi-asserted-by":"publisher","first-page":"e001743","DOI":"10.1136\/jitc-2020-001743","volume":"9","author":"A Nissani","year":"2021","unstructured":"Nissani, A. et al. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. J. Immunother. Cancer 9, e001743 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"71082_CR50","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","volume":"23","author":"ME Dudley","year":"2005","unstructured":"Dudley, M. E. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346\u20132357 (2005).","journal-title":"J. Clin. Oncol."},{"key":"71082_CR51","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1084\/jem.188.2.277","volume":"188","author":"WW Overwijk","year":"1998","unstructured":"Overwijk, W. W. et al. gp100\/pmel 17 is a murine tumor rejection antigen: induction of\u2019self\u2019- reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277\u2013286 (1998).","journal-title":"J. Exp. Med."},{"key":"71082_CR52","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1084\/jem.20030590","volume":"198","author":"WW Overwijk","year":"2003","unstructured":"Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569\u2013580 (2003).","journal-title":"J. Exp. Med."},{"key":"71082_CR53","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"71082_CR54","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1073\/pnas.242600099","volume":"99","author":"C Yee","year":"2002","unstructured":"Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99, 16168\u201316173 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71082_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss, M. et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat. Commun. 8, 1738 (2017).","journal-title":"Nat. Commun."},{"key":"71082_CR56","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984\u2013997.e24 (2018).","journal-title":"Cell"},{"key":"71082_CR57","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","volume":"124","author":"M Morotti","year":"2021","unstructured":"Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759\u20131776 (2021).","journal-title":"Br. J. Cancer"},{"key":"71082_CR58","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248\u2013262 (2017).","journal-title":"Cell Rep."},{"key":"71082_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah4573","volume":"356","author":"AC Villani","year":"2017","unstructured":"Villani, A. C. et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 356, eaah4573 (2017).","journal-title":"Science"},{"key":"71082_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59904-x","volume":"16","author":"G Cheloni","year":"2025","unstructured":"Cheloni, G. et al. Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire. Nat. Commun. 16, 4819 (2025).","journal-title":"Nat. Commun."},{"key":"71082_CR61","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00262-022-03287-1","volume":"72","author":"K Owen","year":"2023","unstructured":"Owen, K., Ghaly, R., Shohdy, K. S. & Thistlethwaite, F. Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis. Cancer Immunol. Immunother. 72, 805\u2013814 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"71082_CR62","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.ymthe.2023.07.015","volume":"31","author":"MD Tennant","year":"2023","unstructured":"Tennant, M. D., New, C., Ferreira, L. M. R. & O\u2019Neil, R. T. Efficient T cell adoptive transfer in lymphoreplete hosts mediated by transient activation of Stat5 signaling. Mol. Ther. 31, 2591\u20132599 (2023).","journal-title":"Mol. Ther."},{"key":"71082_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39225-7","volume":"14","author":"D Li","year":"2023","unstructured":"Li, D. et al. A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8+ T cell therapy in patients with advanced solid tumors. Nat. Commun. 14, 3447 (2023).","journal-title":"Nat. Commun."},{"key":"71082_CR64","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"71082_CR65","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013.e20 (2018).","journal-title":"Cell"},{"key":"71082_CR66","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71082_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg7995","volume":"9","author":"D Barras","year":"2024","unstructured":"Barras, D. et al. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma. Sci. Immunol. 9, eadg7995 (2024).","journal-title":"Sci. Immunol."},{"key":"71082_CR68","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71082-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71082-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71082-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:02:31Z","timestamp":1778691751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71082-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71082"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71082-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4337"}}